US FDA panel backs Moderna coronavirus booster shot for older and high-risk people

Name: ‘Shots while chasing jackpots’: pachinko parlour becomes vaccine centre in Japanese city of Osaka
Uploaded: 2021-10-14T20:07:11.000Z
Duration: 58 s
Description: ‘Shots while chasing jackpots’: pachinko parlour becomes vaccine centre in Japanese city of Osaka

The pharmaceutical firm is seeking authorisation for a half-strength third dose containing 50 micrograms of vaccine

The group of expert advisers to the Food and Drug Administration will weigh whether to make a similar recommendation for J&J’s vaccine on Friday

Reading Time:1 minute

Why you can trust SCMP

If the FDA signs off on Moderna’s booster, the US Centres for Disease Control and Prevention will make specific recommendations on who should get the shots. Photo: AP

Reuters

Published: 4:07am, 15 Oct 2021Updated: 4:07am, 15 Oct 2021

A panel of expert advisers to the US Food and Drug Administration unanimously voted on Thursday to recommend booster shots of Moderna Inc’s Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness.

If the FDA signs off on Moderna’s booster, the US Centres for Disease Control and Prevention will make specific recommendations on who should get the shots. CDC advisers are expected to meet next week.

The FDA’s Vaccines and Related Biological Products Advisory Committee met on Thursday to consider the additional dose of the Moderna vaccine and will weigh whether to make a similar recommendation for Johnson & Johnson’s vaccine on Friday.

The vote to back Moderna’s booster was 19-0.

00:58

‘Shots while chasing jackpots’: pachinko parlour becomes vaccine centre in Japanese city of Osaka

Moderna is seeking authorisation of a booster that contains 50 micrograms of vaccine, half of strength of its regular dose but still higher than the Pfizer/BioNTech shot at 30 micrograms.

Select Voice

Choose your listening speed

Get through articles 2x faster

1.25x

250 WPM

Slow

Average

Fast

00:0000:00

1.25x